Massie, Barry M.

Irbesartan in patients with heart failure and preserved ejection fraction

Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,960

Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure

Packer, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G. F., Horowitz, J. D., Massie, B. M., Rydén, L., Thygesen, K., & Uretsky, B. F. (1999) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 1,244

Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction

Zile, M. R., Gottdiener, J. S., Hetzel, S. J., McMurray, J. J., Komajda, M., McKelvie, R., Baicu, C. F., Massie, B. M., & Carson, P. E. (2011) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 517

Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial

Haass, M., Kitzman, D. W., Anand, I. S., Miller, A., Zile, M. R., Massie, B. M., & Carson, P. E. (2011) · Circulation: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 366

A comparative analysis of the results from 4 trials of β-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS

Domanski, M. J., Krause-Steinrauf, H., Massie, B. M., Deedwania, P., Follmann, D., Kovar, D., Murray, D., Oren, R., Rosenberg, Y., Young, J., et al. (2003) · Journal of Cardiac Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 176

Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality

Davison, B. A., Metra, M., Senger, S., Edwards, C., Milo, O., Bloomfield, D. M., Cleland, J. G., Dittrich, H. C., Givertz, M. M., O’Connor, C. M., et al. (2016) · European Journal of Heart Failure

Heart Failure Treatment and ManagementAcute Myocardial Infarction Research

Cited by 67

Effects of chronic methadone administration on the hypothalamic-pituitary-thyroid axis

SHENKMAN, L., MASSIE, B., MITSUMA, T., & HOLLANDER, C. S. (1972) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsNeuropeptides and Animal Physiology

Cited by 28

Intensive glycemic control improves long-term renal outcomes in type 2 diabetes in the Veterans Affairs Diabetes Trial (VADT)

Agrawal, L., Azad, N., Bahn, G. D., Reaven, P. D., Hayward, R. A., Reda, D. J., Emanuele, N. V., VADT Study Group, Abraira, C., Duckworth, W. C., et al. (2019) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 20